Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Database
Language
Publication year range
2.
Int J Toxicol ; 39(2): 124-130, 2020.
Article in English | MEDLINE | ID: mdl-32066300

ABSTRACT

Intrathecal administration is an important route for drug delivery, and in pharmacology and toxicology studies, cerebrospinal fluid (CSF) collection and analysis is required for evaluating blood-brain barrier penetration and central nervous system exposure. The characteristics of CSF in commonly used nonrodent models are lacking. The purpose of this study is to evaluate and provide some insights into normal cellular and biochemical composition of CSF as well as diffusion potential following intrathecal injection across several nonrodent species. Cerebrospinal fluid samples were collected from the cerebellomedullary cistern of beagle dogs, cynomolgus monkeys, and Göttingen minipigs and analyzed for clinical chemistry and cytological evaluation. Diffusion into the intrathecal space following intrathecal injection was assessed following administration of a contrast agent using fluoroscopy. The predominant cell types identified in CSF samples were lymphocytes and monocytoid cells; however, lymphocytes were represented in a higher percentage in dogs and monkeys as opposed to monocytoid cells in minipigs. Clinical chemistry parameters in CSF revealed higher Cl- concentrations than plasma, but lower K+, Ca2+, phosphorus, glucose, creatinine, and total protein levels consistent across all 3 species. Diffusion rates following intrathecal injection of iodixanol showed some variability with dogs, showing the greatest diffusion distance; however, the longest diffusion time through the intervertebral space, followed by monkeys and minipigs. Minimal diffusion was observed in minipigs, which could have been attributed to anatomical spinal constraints that have been previously identified in this species.


Subject(s)
Cerebrospinal Fluid/chemistry , Animals , Cell Count , Cerebrospinal Fluid/cytology , Contrast Media/pharmacokinetics , Dogs , Female , Injections, Spinal , Lumbar Vertebrae , Macaca fascicularis , Male , Swine , Swine, Miniature , Triiodobenzoic Acids/cerebrospinal fluid , Triiodobenzoic Acids/pharmacokinetics
3.
Cell Rep ; 27(13): 3902-3915.e6, 2019 06 25.
Article in English | MEDLINE | ID: mdl-31242422

ABSTRACT

Neutrophils are phenotypically heterogeneous and exert either anti- or pro-metastatic functions. We show that cancer-cell-derived G-CSF is necessary, but not sufficient, to mobilize immature low-density neutrophils (iLDNs) that promote liver metastasis. In contrast, mature high-density neutrophils inhibit the formation of liver metastases. Transcriptomic and metabolomic analyses of high- and low-density neutrophils reveal engagement of numerous metabolic pathways specifically in low-density neutrophils. iLDNs exhibit enhanced global bioenergetic capacity, through their ability to engage mitochondrial-dependent ATP production, and remain capable of executing pro-metastatic neutrophil functions, including NETosis, under nutrient-deprived conditions. We demonstrate that NETosis is an important neutrophil function that promotes breast cancer liver metastasis. iLDNs rely on the catabolism of glutamate and proline to support mitochondrial-dependent metabolism in the absence of glucose, which enables sustained NETosis. These data reveal that distinct pro-metastatic neutrophil populations exhibit a high degree of metabolic flexibility, which facilitates the formation of liver metastases.


Subject(s)
Liver Neoplasms/metabolism , Mammary Neoplasms, Experimental/metabolism , Neutrophils/metabolism , Animals , Cell Line, Tumor , Female , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Mammary Neoplasms, Experimental/pathology , Mice , Mice, Inbred BALB C , Neoplasm Metastasis , Neutrophils/pathology
4.
Vet Clin Pathol ; 45(3): 459-65, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27538028

ABSTRACT

This is the report of a 5-year-old male neutered Great Dane with an extreme leukocytosis (544.9 × 10(9) cells/L; RI 5.2-13.9 × 10(9) cells/L) characterized by highly atypical round cells. Cellular morphologic features such as cytoplasmic membrane blebs, a high nuclear-to-cytoplasmic ratio, and nuclear indentations and irregularities and large nucleoli, as well as immunocytochemistry for CD3 and CD79, myeloperoxidase cytochemistry, and clonality testing were not conclusive for myeloid or lymphoid origin. Marked alkaline hyperphosphatasemia was present at the first visit (2783.0 U/L; RI 6-80.0 U/L), followed by a 5-fold increase (14,000 U/L) a week later, identified as being mostly contributed by the bone-ALP isoform (11,062 U/L; RI 0-30 U/L). In addition, the atypical leukocytes were strongly positive for cytoplasmic ALP activity. In vitro lysis of a heparin blood sample resulted in a 1.7-fold increase of ALP activity, supporting the origin of the hyperphosphatasemia at least in part from the leukemic cell population. To the authors' knowledge, this is a unique case of alkaline hyperphosphatasemia, due at least to a leukemic cell population producing a bone-ALP isoform, regardless of the exact nature of the leukemia.


Subject(s)
Alkaline Phosphatase/blood , Dog Diseases/blood , Leukemia, Myeloid, Acute/veterinary , Leukocytes/enzymology , Acute Disease , Animals , Dogs , Leukemia, Myeloid, Acute/blood , Male
6.
Blood ; 128(2): 185-94, 2016 07 14.
Article in English | MEDLINE | ID: mdl-27166360

ABSTRACT

The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical data suggest that HDIs augment the effect of rituximab. In this randomized phase 2 study, we evaluated the response rate and toxicity of panobinostat, a pan-HDI administered 30 mg orally 3 times weekly, with or without rituximab, in 40 patients with relapsed or refractory de novo (n = 27) or transformed (n = 13) DLBCL. Candidate genes and whole exomes were sequenced in relapse tumor biopsies to search for molecular correlates, and these data were used to quantify circulating tumor DNA (ctDNA) in serial plasma samples. Eleven of 40 patients (28%) responded to panobinostat (95% confidence interval [CI] 14.6-43.9) and rituximab did not increase responses. The median duration of response was 14.5 months (95% CI 9.4 to "not reached"). At time of data censoring, 6 of 11 patients had not progressed. Of the genes tested for mutations, only those in MEF2B were significantly associated with response. We detected ctDNA in at least 1 plasma sample from 96% of tested patients. A significant increase in ctDNA at day 15 relative to baseline was strongly associated with lack of response (sensitivity 71.4%, specificity 100%). We conclude that panobinostat induces very durable responses in some patients with relapsed DLBCL, and early responses can be predicted by mutations in MEF2B or a significant change in ctDNA level at 15 days after treatment initiation. This clinical trial was registered at www.ClinicalTrials.gov (#NCT01238692).


Subject(s)
Hydroxamic Acids/administration & dosage , Indoles/administration & dosage , Lymphoma, Large B-Cell, Diffuse/drug therapy , Rituximab/administration & dosage , Adult , Aged , DNA, Neoplasm/blood , DNA, Neoplasm/genetics , Female , Humans , Lymphoma, Large B-Cell, Diffuse/blood , Lymphoma, Large B-Cell, Diffuse/genetics , MEF2 Transcription Factors/blood , MEF2 Transcription Factors/genetics , Male , Middle Aged , Mutation , Neoplasm Proteins/blood , Neoplasm Proteins/genetics , Panobinostat , Recurrence
7.
Clin Cancer Res ; 22(9): 2290-300, 2016 05 01.
Article in English | MEDLINE | ID: mdl-26647218

ABSTRACT

PURPOSE: Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of patients, and yet little is known about its biology. EXPERIMENTAL DESIGN: Using exome sequencing, we characterized the mutation profiles of 38 rrDLBCL biopsies obtained at the time of progression after immunochemotherapy. To identify genes that may be associated with relapse, we compared the mutation frequency in samples obtained at relapse to an unrelated cohort of 138 diagnostic DLBCLs and separately amplified specific mutations in their matched diagnostic samples to identify clonal expansions. RESULTS: On the basis of a higher frequency at relapse and evidence for clonal selection, TP53, FOXO1, MLL3 (KMT2C), CCND3, NFKBIZ, and STAT6 emerged as top candidate genes implicated in therapeutic resistance. We observed individual examples of clonal expansions affecting genes whose mutations had not been previously associated with DLBCL including two regulators of NF-κB: NFKBIE and NFKBIZ We detected mutations that may be affect sensitivity to novel therapeutics, such as MYD88 and CD79B mutations, in 31% and 23% of patients with activated B-cell-type of rrDLBCL, respectively. We also identified recurrent STAT6 mutations affecting D419 in 36% of patients with the germinal center B (GCB) cell rrDLBCL. These were associated with activated JAK/STAT signaling, increased phospho-STAT6 protein expression and increased expression of STAT6 target genes. CONCLUSIONS: This work improves our understanding of therapeutic resistance in rrDLBCL and has identified novel therapeutic opportunities especially for the high-risk patients with GCB-type rrDLBCL. Clin Cancer Res; 22(9); 2290-300. ©2015 AACR.


Subject(s)
Lymphoma, Large B-Cell, Diffuse/genetics , Neoplasm Recurrence, Local/genetics , Adult , Aged , B-Lymphocytes/metabolism , CD79 Antigens/genetics , Cyclin D3/genetics , Female , Forkhead Box Protein O1/genetics , Gene Expression Regulation, Neoplastic/genetics , Germinal Center/metabolism , Humans , Janus Kinases/genetics , Male , Middle Aged , Mutation/genetics , Myeloid Differentiation Factor 88/genetics , Myeloid-Lymphoid Leukemia Protein/genetics , NF-kappa B/genetics , Nuclear Proteins/genetics , Prospective Studies , STAT6 Transcription Factor/genetics , Signal Transduction/genetics , Tumor Suppressor Protein p53/genetics
8.
Can Vet J ; 56(12): 1287-91, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26663927

ABSTRACT

This is a case of bilateral renal T-cell lymphoma associated with secondary erythrocytosis in a dog. This case is distinctive in using clonality combined with immunocytochemistry to support the diagnosis, thus emphasizing the utility of cytology slides when histology is unavailable. This combination may be a unique canine lymphoma entity.


Lymphome à cellules T rénal bilatéral avec infiltration hépatique et polycythémie secondaire chez un chien : utilité des lames de cytologie. Nous présentons un cas de lymphome à cellules T rénal bilatéral associé à une érythrocytose secondaire chez un chien. Ce cas est distinct parce qu'il fait appel à la clonalité combinée à l'immunocytochimie pour appuyer le diagnostic, ce qui souligne l'utilité des lames de cytologie lorsqu'une histologie n'est pas disponible. Cette combinaison pourrait être une entité unique de lymphome canin.(Traduit par Isabelle Vallières).


Subject(s)
Dog Diseases/diagnosis , Kidney Neoplasms/veterinary , Liver Neoplasms/secondary , Lymphoma, T-Cell/veterinary , Polycythemia/veterinary , Animals , Dog Diseases/pathology , Dogs , Kidney Neoplasms/complications , Kidney Neoplasms/pathology , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/pathology , Male , Polycythemia/etiology , Polycythemia/pathology
SELECTION OF CITATIONS
SEARCH DETAIL